Lumida
/ANNX
⌘K
Annexon Inc

Annexon Inc

ANNX
$3.94USD↓-4.83%-0.20 today

MARKET CAP

746.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $4

52W RANGE

$2
$7

AI Summary

Stalk
Sell NowMedium

ANNX is in a Stage 3 distribution phase, trading below its 9, 20, and 50 EMAs after failing to sustain rallies. Medium-term bias is bearish, favoring sells on rallies into the dynamic resistance zone around the short-term EMAs. Short-term rejection at the EMAs confirms immediate execution. Long-term trend remains up above the 200-day SMA but is at risk if price breaks decisively lower.

  • ↑90% response rate at week 1 in FORWARD GBS trial underpins efficacy case.
  • ↑ARCHER II enrollment boost and added month 24 endpoint could drive blockbuster status.
  • ↓FDA approval risk remains with pending month 24 Phase III data for GBS and GA.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Annexon, Inc. (NASDAQ: ANNX) is an emerging biotechnology company engaged in the development of targeted immunotherapies aimed at addressing neuroinflammatory diseases, particularly Guillain-Barré syndrome (GBS) and geographic atrophy (GA). Annexon’s unique therapeutic approach leverages its foundation in C1Q biology, positioning it as a potential leader in treating significant unmet medical needs in the neuroinflammatory space.

Bull says

  • ↑90% response rate at week 1 in FORWARD GBS trial underpins efficacy case.
  • ↑ARCHER II enrollment boost and added month 24 endpoint could drive blockbuster status.
  • ↑$200M credit facility extends cash runway into 2028, funding key trials.
  • ↑Q2 revenue $10M (+50% YoY) and cash $120M highlight strong liquidity.
  • ↑Significant institutional support via high 13F ownership reflects investor confidence.
  • ↑Addressable market of 22,000 annual GBS cases underscores major unmet need.

Bear says

  • ↓FDA approval risk remains with pending month 24 Phase III data for GBS and GA.
  • ↓Negative earnings yield and weak profitability reflect mounting financial pressure.
  • ↓Net loss $10M in Q2; operating expenses +30% YoY raise cash burn concerns.
  • ↓Lower patient retention in ARCHER II trial may impair pivotal results.
  • ↓High leverage risk from $200M facility increases financial strain despite runway.
  • ↓Intense competition from Regeneron, Biogen, Novartis, and Lilly may erode market share.

Investment themes with ANNX

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q2 2026 · Mgmt. Guidance

Updated 08-17-2026bullish

Transcript signals

Bull points

  • The strong power and execution of our Phase III ARCHER II trial provide a clear opportunity to seamlessly incorporate a month 24 dual primary endpoint while maintaining the month 15 primary endpoint.
  • Importantly, as ARCHER2 was already designed to remain masked through month 24, this strategic addition allows us to evaluate the longer-term profile of VaN improvement for inclusion into the label without change to the study operation.
  • The ARCHER II study, including month 24 analyses, is expected to be completed in the third quarter of 2027.
Read full transcript analysis ›